Cargando…

Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)

BACKGROUND: S-1, an oral fluoropyrimidine, plus cisplatin (SP) is a standard regimen for advanced gastric cancer (AGC) in East Asia. To date, no studies have evaluated the efficacy and safety of trastuzumab combined with SP in patients with human epidermal growth factor receptor type 2 (HER2)-positi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurokawa, Y, Sugimoto, N, Miwa, H, Tsuda, M, Nishina, S, Okuda, H, Imamura, H, Gamoh, M, Sakai, D, Shimokawa, T, Komatsu, Y, Doki, Y, Tsujinaka, T, Furukawa, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950868/ https://www.ncbi.nlm.nih.gov/pubmed/24473399 http://dx.doi.org/10.1038/bjc.2014.18

Ejemplares similares

Randomized, Open‐Label Phase II Study Comparing Capecitabine‐Cisplatin Every 3 Weeks with S‐1‐Cisplatin Every 5 Weeks in Chemotherapy‐Naïve Patients with HER2‐Negative Advanced Gastric Cancer: OGSG1105, HERBIS‐4A Trial
por: Kawakami, Hisato, et al.
Publicado: (2018)

The best of Herbie Hancock
por: Hancock, Herbie, 1940-
Publicado: (1988)

Libellus de medicinalibus Indorum herbis : manuscrito azteca de 1552 /
por: Cruz, Martín de la
Publicado: (2017)

Libellus de medicinalibus Indorum herbis : manuscrito azteca de 1552 /
por: Cruz, Martín de la
Publicado: (1991)

Libellus de medicinalibus indorum herbis. : manuscrito azteca de 1552
por: Cruz, Martín de la
Publicado: (1964)

The Determination of Some Microbiological and Chemical Features in Herby Cheese
por: Ekici, Kamil, et al.
Publicado: (2019)

Estudios actuales sobre el Libellus de medicinalibus Indorum herbis /
Publicado: (1992)

Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma
por: Catenacci, D.V.T., et al.
Publicado: (2021)

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
por: Park, Y H, et al.
Publicado: (2014)

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
por: Kawaguchi, Y, et al.
Publicado: (2007)

Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment
por: An, E., et al.
Publicado: (2017)

YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
por: Fujihara, Miwa, et al.
Publicado: (2021)

Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)
por: Kawamoto, Yasuyuki, et al.
Publicado: (2022)

WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial
por: Varlet, Pascale, et al.
Publicado: (2020)

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
por: Yu, Y. F., et al.
Publicado: (2017)

HER2 Is Frequently Over‐expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab
por: Fujimura, Masaki, et al.
Publicado: (2002)

Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy
por: Pereira, Patrícia M. R., et al.
Publicado: (2018)

Effects of an oral elemental nutritional supplement in gastric cancer patients with adjuvant S‐1 chemotherapy after gastrectomy: A multicenter, open‐label, single‐arm, prospective phase II study (OGSG1108)
por: Imamura, Hiroshi, et al.
Publicado: (2021)

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
por: Tsang, R Y, et al.
Publicado: (2012)

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
por: Yamada, Y, et al.
Publicado: (2018)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients
por: Park, Y H, et al.
Publicado: (2009)

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2023)

Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma
por: Miyagaki, H, et al.
Publicado: (2012)

Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18
por: Kim, M., et al.
Publicado: (2023)

MZ1 co-operates with trastuzumab in HER2 positive breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2021)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
por: Sakai, Hitomi, et al.
Publicado: (2018)

Plant-Made Trastuzumab (Herceptin) Inhibits HER2/Neu+ Cell Proliferation and Retards Tumor Growth
por: Komarova, Tatiana V., et al.
Publicado: (2011)

Phase 2 trial of neoadjuvant docetaxel, oxaliplatin, and S‐1 for clinical stage III gastric or esophagogastric junction adenocarcinoma
por: Kurokawa, Yukinori, et al.
Publicado: (2022)

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
por: Mills, Matthew N., et al.
Publicado: (2021)

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
por: Kang, Y-K, et al.
Publicado: (2014)

Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy
por: Zakaria, Nermine H., et al.
Publicado: (2023)

Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
por: Sawaki, Akira, et al.
Publicado: (2011)

A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment
por: Du, F., et al.
Publicado: (2016)

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
por: Corrêa, Tatiana Strava, et al.
Publicado: (2018)

A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients
por: Zhu, Bo, et al.
Publicado: (2015)

Expression of MALAT1 Promotes Trastuzumab Resistance in HER2 Overexpressing Breast Cancers
por: Wu, Yanyuan, et al.
Publicado: (2020)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019)

C20orf20 (MRG-binding protein) as a potential therapeutic target for colorectal cancer
por: Yamaguchi, K, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_uq122j2lulcl7rf7c2iq17fp0b